Relay Therapeutics (RLAY) Scheduled to Post Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAY) will be issuing its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.

Relay Therapeutics (NASDAQ:RLAY) last posted its earnings results on Thursday, February 22nd. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.09. Relay Therapeutics had a negative return on equity of 42.43% and a negative net margin of 1,263.49%. During the same period last year, the firm earned ($0.56) EPS. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Trading Up 3.9 %

Shares of RLAY stock traded up $0.24 on Friday, hitting $6.40. 77,366 shares of the stock were exchanged, compared to its average volume of 1,139,714. The firm has a market capitalization of $846.98 million, a PE ratio of -2.29 and a beta of 1.63. Relay Therapeutics has a one year low of $5.70 and a one year high of $13.32. The firm’s 50 day moving average is $8.33 and its two-hundred day moving average is $8.84.

Analyst Upgrades and Downgrades

RLAY has been the topic of a number of recent analyst reports. Stifel Nicolaus lifted their price objective on Relay Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Leerink Partnrs reiterated an “outperform” rating on shares of Relay Therapeutics in a research note on Thursday, February 22nd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $26.00.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.